Clearmind’s CMND-100 Shows Continued Safety in Phase I/IIa AUD Trial
Event summary
- Clearmind Medicine reported successful ongoing treatment of participants in the third cohort of its FDA-approved Phase I/IIa trial for CMND-100, a non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder (AUD).
- No serious adverse events were reported at U.S. sites Yale University and Johns Hopkins University.
- The multinational, multicenter study aims to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in moderate to severe AUD patients.
The big picture
Clearmind’s progress with CMND-100 underscores the growing interest in non-hallucinogenic psychedelic-based therapies for AUD, a condition with significant unmet medical needs. The involvement of prestigious institutions like Yale and Johns Hopkins lends credibility to the trial’s design and execution, potentially accelerating regulatory and commercial pathways.
What we're watching
- Trial Momentum
- Whether Clearmind can sustain enrollment and positive results across all cohorts.
- Regulatory Pathway
- The pace at which CMND-100 advances through subsequent clinical phases.
- Competitive Positioning
- How Clearmind differentiates CMND-100 in the growing neuroplastogen-derived therapeutics market.
Related topics